内皮抑素对人肺腺癌A549细胞周期及HIF-1表达的影响  

Effects of Endostar on Cell Cycle and HIF-1 Expression of Human Lung Cancer A549

作　　者：张彦彦[1] 戈伟[1] 赵娟[1] 赵振宇[1] 李长虎[1] 

机构地区：[1]武汉大学人民医院肿瘤诊疗中心,430060

出　　处：《肿瘤防治研究》2010年第1期16-19,共4页Cancer Research on Prevention and Treatment

摘　　要：目的研究内皮抑素在体外对人肺腺癌细胞A549的影响及机制。方法流式细胞术(FCM)检测内皮抑素治疗后,肺腺癌细胞A549的细胞周期分布;酶联免疫吸附法(ELISA)检测处理前后细胞中HIF-1的表达情况。结果内皮抑素处理肺腺癌A549细胞,可以使该细胞S期和G2/M期细胞比例增多,抑制HIF-1的表达,且随处理时间的延长,HIF-1的抑制率不断提高。结论内皮抑素可以使A549细胞阻滞在G2/M期及S期的比例明显增加,从而为其他手段抑制A549细胞的增殖或直接杀伤A549细胞提供了基础;内皮抑素可以抑制肿瘤细胞的HIF-1表达,HIF-1是肿瘤细胞耐受放化疗的因素之一,因此联合内皮抑素治疗有可能提高放、化疗疗效。Objective To investigate the effect of endostar on human lung cancer line A549 and the action machanism. Methods A549 cells were treated with endostar. The cell cycle was detected by flow cytometry（FCM）, and the expression of HIF-1 by enzyme linked immunosorbent assay（ELISA）. Results Endostar could arrest A549 cells in G2 ~M and S phases, and inhibit the expression of HIF-1 with the inhibition rate being increased with the time. Conclusion Endostar can increase the proportion of A549 cells in G2/M and S phases, which provides the basis for the inhibition of A549 cell proliferation. HIF-1 is an important factor in resistantce of chemotherapy and radiotherapy. Endostar can inhibit the production of HIF-1 in tumor cells, so combined used of endostatin maybe improve the curative effects of radiotherapy and chemotherapy.

关 键 词：非小细胞肺癌 内皮抑素 细胞周期 HIF-1 

分 类 号：R734.2[医药卫生—肿瘤]